(Wegovy, Mounjaro & the New Pill, 2026) Updated 22/06/26 Based on the available clinical evidence, Mounjaro (tirzepatide) and Wegovy (semaglutide) are both well tolerated, but most people find Mounjaro causes fewer gastrointestinal side effects at comparable doses, with lower rates of nausea and a higher likelihood of completing treatment
Why were they not blinded
Under the brand name Wegovy, it is indicated for weight management in non-diabetic populations with weight-related comorbidities [6, 7]
Some medications are becoming more challenging to locate , and shortages are becoming more common
Whether the dose-reduction strategy translates as cleanly for someone using the drug for both type 2 diabetes and weight management is a different question
it directly affects the medications: Potency Safety Stability Expected results If tirzepatide is exposed to temperatures outside the recommended range, even for short periods, it may not work as effectively